


**Amendments to the Claims:**

**This listing of claims will replace all prior versions and listings of claims in the application.**

**Listing of Claims:**

Claim 1 (currently amended): A quinazoline derivative of the formula I:



wherein:

**each of  $R^1$  and  $R^2$** , which may be the same or different, is selected from hydrogen, carboxy, cyano, formyl, (1-3C)alkyl, (2-3C)alkanoyl, (1-3C)alkoxycarbonyl, carbamoyl, N-(1-3C)alkylcarbamoyl and N, N-di-[(1-3C)alkyl]carbamoyl;

**each of  $R^{1a}$  and  $R^{2a}$** , which may be the same or different, is selected from hydrogen and (1-3C)alkyl;

**each of  $R^3$  and  $R^4$** , which may be the same or different, is selected from ~~hydrogen, (1-3C)alkyl and (2-4C) alkenyl; and,~~

wherein any CH or CH<sub>2</sub> or CH<sub>3</sub> within any of  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$  and  $R^4$  optionally bears on each said CH or CH<sub>2</sub> or CH<sub>3</sub> ~~one or more halogeno substituents or a substituent selected from hydroxy, cyano, and (1-3C)alkoxy, amino, (2-3C)alkanoyl, (1-3C)alkylamino and di-[(1-3C)alkyl]amino;~~

X is selected from hydrogen, halogeno, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

each  $R^5$ , which may be the same or different, is selected from halogeno, hydroxy, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

Y is selected from a direct bond, O, S,  $OC(R^7)_2$ ,  $SC(R^7)_2$ , SO,  $SO_2$ ,  $N(R^7)$ , CO and  $N(R^7)C(R^7)_2$  wherein each  $R^7$  is, independently, hydrogen or (1-6C)alkyl;

$Q^1$  is selected from phenyl, pyridyl, pyrazinyl, 1,3-thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1,3-oxazolyl and isoxazolyl, and

wherein  $Q^1$  optionally bears one or more substituents, which may be the same or different, selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfanyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or from a group of the formula:  $-X^1-R^8$ ; wherein

$X^1$  is a direct bond or is selected from O, CO and  $N(R^9)$ , wherein;

$R^9$  is hydrogen or (1-6C)alkyl, and;

$R^8$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, N-(1-6C)alkylamino-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, (2-6C)alkanoyl-(1-6C)alkyl or (1-6C)alkoxycarbonyl-(1-6C)alkyl, and

wherein any  $CH_2$  or  $CH_3$  within a substituent on  $Q^1$  optionally bears on each said  $CH_2$  or  $CH_3$  one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino;

$R^6$  is selected from hydrogen, (1-6C)alkoxy, (2-6C)alkenyloxy and (2-6C)alkynyloxy, and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy;  
n is 0, 1, 2 or 3;  
or a pharmaceutically acceptable salt thereof.

Claim 2 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>1</sup> is selected from hydrogen, methyl and ~~ethyl~~, ethyl; R<sup>2</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N, N-di-methylcarbamoyl, N, N-di-methylcarbamoyl; and R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 3 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>2</sup> is selected from hydrogen, methyl and ~~ethyl~~, ethyl; R<sup>1</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N, N-di-methylcarbamoyl, N, N-di-methylcarbamoyl; and R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 4 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>1</sup> and R<sup>1a</sup> are each ~~hydrogen~~, hydrogen; R<sup>2</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N, N-di-methylcarbamoyl, N, N-di-methylcarbamoyl; and R<sup>2a</sup> is selected from hydrogen and (1-3C)alkyl.

Claim 5 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>2</sup> and R<sup>2a</sup> are each ~~hydrogen~~, hydrogen; R<sup>1</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N, N-di-methylcarbamoyl, N, N-di-methylcarbamoyl; and R<sup>1a</sup> is selected from hydrogen and (1-3C)alkyl.

Claim 6 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>1</sup> is methyl; and R<sup>2</sup>, R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 7 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>2</sup> is methyl; and R<sup>1</sup>, R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 8 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>1</sup> and R<sup>1a</sup> are each methyl; and R<sup>2</sup> and R<sup>2a</sup> are each hydrogen.

Claim 9 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein R<sup>2</sup> and R<sup>2a</sup> are each methyl; and R<sup>1</sup> and R<sup>1a</sup> are each hydrogen.

Claim 10 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from (1-3C)alkyl, wherein any CH or CH<sub>2</sub> or CH<sub>3</sub> within any of R<sup>3</sup> and R<sup>4</sup> optionally bears on each said CH or CH<sub>2</sub> or CH<sub>3</sub> one or more substituents selected from hydroxy and (1-3C)alkoxy.

Claim 11 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from ~~hydrogen~~, methyl, ethyl, propenyl, 2-methoxyethyl and 2-hydroxyethyl.

Claim 12 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 11, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from methyl, ethyl, propenyl, 2-methoxyethyl and 2-hydroxyethyl.

Claim 13 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 11, wherein R<sup>3</sup> is methyl and R<sup>4</sup> is selected from methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl and propenyl.

Claim 14 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 10, wherein R<sup>3</sup> and R<sup>4</sup> are each methyl.

Claim 15 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 10, wherein R<sup>3</sup> is ethyl and R<sup>4</sup> is 2-hydroxyethyl.

Claim 16 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein X is selected from hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy.

Claim 17 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 16, wherein X is selected from hydrogen, fluoro, chloro, methyl and methoxy.

Claim 18 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 16, wherein X is selected from methyl and chloro.

Claim 19 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 18, wherein X is chloro.

Claim 20 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 18, wherein X is methyl.

Claim 21 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein Y is selected from O, S and OC(R<sup>7</sup>)<sub>2</sub> wherein each R<sup>7</sup> is, independently, hydrogen or (1-4C)alkyl.

Claim 22 (currently amended): ~~A~~ The quinazoline derivative of ~~the~~ formula I as defined in claim 21, wherein Y is selected from O, S and OCH<sub>2</sub>.

Claim 23 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 21, wherein Y is O.

Claim 24 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 21, wherein Y is S.

Claim 25 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 21, wherein Y is OCH<sub>2</sub>.

Claim 26 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein n is 0.

Claim 27 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 1, wherein Q<sup>1</sup> is selected from phenyl, 2-pyridyl, 2-pyrazinyl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1H-imidazol-2-yl and isoxazol-3-yl, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, as defined in claim 1.

Claim 28 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 27, wherein Q<sup>1</sup> is selected from phenyl, 2-pyridyl, 2-pyrazinyl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1H-imidazol-2-yl and 3-isoxazolyl, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, selected from fluoro and (1-4C)alkyl.

Claim 29 (currently amended): ~~A~~The quinazoline derivative of ~~the~~ formula I as defined in claim 27, wherein Q<sup>1</sup> is selected from 3-fluorophenyl, 2-pyridyl, 2-pyrazinyl, 1-methyl-1H-imidazol-2-yl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl and 5-methyl-3-isoxazolyl.

Claim 30 (currently amended): ~~A~~The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>6</sup> is hydrogen.

Claim 31 (currently amended): A The quinazoline derivative as defined in claim 1 selected from the following:

4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(1-methyl-1*H*-imidazol-2-ylthio)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(1-methyl-1*H*-imidazol-2-ylthio)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
4-(4-(3-Fluorobenzyloxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(4-(3-Fluorobenzyloxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyrazinylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyrazinylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-(2-(*N*-ethyl-*N*-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-[2-(*N*-(2-hydroxyethyl)-*N*-methylamino)ethoxy]-quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-(*N*-ethyl-*N*-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-(*N*-(2-hydroxyethyl)-*N*-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyridin-2-yloxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

*N*-{3-Chloro-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-{3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-[3-methyl-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(~~dimethylamino~~Dimethylamino)-1-methylethoxy]-*N*-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-{3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;



5-[2-(~~dimethylamino~~Dimethylamino)-2-methylpropoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-N-{3-methoxy-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-N-[3-methoxy-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-N-[3-fluoro-4-(1,3-thiazol-5-ylmethoxy)phenyl]quinazolin-4-amine;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(2*S*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(2*R*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;

5-{2-[Allyl(methyl)amino]ethoxy}-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

2-[ {2-[(4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}(ethyl)amino]ethanol;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-[(2-methoxyethyl)(methyl)amino]-1-methylethoxy}quinazolin-4-amine;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-[ethyl(methyl)amino]-1-methylethoxy}quinazolin-4-amine;

5-[(1*R*)-2-[Allyl(methyl)amino]-1-methylethoxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*S*)-2-[Allyl(methyl)amino]-1-methylethoxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(2*S*)-2-(dimethylamino)propyl]oxy}-quinazolin-4-amine;


*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-{[(2*R*)-2-(dimethylamino)propyl]oxy}-quinazolin-4-amine;  
*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-{[(2*S*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;  
*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-{[(2*R*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;  
*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;  
5-[2-(Dimethylamino)-1-methylethoxy]-*N*-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine;  
5-[2-(Dimethylamino)-1-methylethoxy]-*N*-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine;  
and  
*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]quinazolin-4-amine;  
or a pharmaceutically acceptable salt thereof.

Claim 32 (original): A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.

Claims 33-36 (cancelled).


Claim 37 (currently amended): A process for ~~the preparation of~~ preparing a quinazoline derivative of ~~the~~ formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 which comprises:

(a) ~~the reaction~~ reacting, ~~conveniently optionally~~ in the presence of a suitable base, of a quinazoline of ~~the~~ formula **II**:



**II**


wherein  $R^5$ ,  $R^6$ ,  $Q^1$ ,  $X$ ,  $Y$  and  $n$  are as defined in claim 1 except that any functional group is optionally protected if necessary; and  $L$  is a displaceable group, with an alcohol of the formula **III**:



**III**


wherein  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$  and  $R^4$  are as defined in claim 1 except that any functional group is optionally protected if necessary; or

- (b) for the preparation of ~~these~~ the compounds of ~~the~~ formula **I** wherein  $Y$  is  $OC(R^7)_2$ ,  $SC(R^7)_2$  or  $N(R^7)C(R^7)_2$ , ~~the reaction~~ reacting, conveniently optionally in the presence of a suitable base, ~~of a~~ of a quinazoline of ~~the~~ formula **IV**:



**IV**


wherein Y is O, S or N(R<sup>7</sup>); and X, R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and n are as defined in claim 1 except that any functional group is optionally protected ~~if necessary~~, with a compound of ~~the~~ formula **V**:



**V**

wherein L<sup>1</sup> is a suitable displaceable group and Q<sup>1</sup> and R<sup>7</sup> are as defined in claim 1 except that any functional group is optionally protected ~~if necessary~~; or

(c) ~~the reaction of~~ reacting a quinazoline of ~~the~~ formula **VI**:



**VI**


wherein L<sup>2</sup> is a suitable displaceable group and Q<sup>1</sup>, X, Y, R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>5</sup>, R<sup>6</sup> and n are as defined in claim 1 except that any functional group is optionally protected ~~if necessary~~, with an amine of ~~the~~ formula **VII**:



**VII**

wherein R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1 except that any functional group is optionally protected ~~if necessary~~; or

(d) for the preparation of ~~these the~~ compounds of the formula **I** wherein R<sup>2a</sup> is hydrogen, the reductive amination in the presence of a suitable reducing agent of the aldehyde or ketone of ~~the~~ formula **VIII**:



**VIII**


wherein  $Q^1$ , X, Y,  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^5$ ,  $R^6$  and n are as defined in claim 1 except that any functional group is optionally protected if necessary, with an amine of the formula **VII**:



**VII**


wherein  $R^3$  and  $R^4$  are as defined in claim 1 except that any functional group is optionally protected if necessary; or

- (e) for the preparation of ~~these the~~ compounds of the formula **I** wherein Y is O or  $N(R^7)$  and  $Q^1$  is 2-pyridyl or 4-pyridyl, ~~the reaction reacting~~, in the presence of a suitable catalyst, of a quinazoline of the formula **IV**:




**IV**

wherein Y is O or  $N(R^7)$ ; and X,  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and n are as defined in claim 1 except that any functional group is optionally protected if necessary, with an amine of the formula **IVa** or of ~~the~~ formula **IVb**:




**IVa**



**IVb**


wherein  $L^3$  is a suitable displaceable group; or

- (f) ~~the reaction~~reacting, conveniently optionally in the presence of a suitable phosphine and a suitable diazo compound, ~~of~~ a quinazoline of the formula **II**:



**II**

wherein  $R^5$ ,  $R^6$ ,  $Q^1$ , X, Y and n are as defined in claim 1 except that any functional group is optionally protected ~~if necessary~~, and  $L^4$  is hydroxy, with an alcohol of the formula **III**:



**III**

wherein  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$  and  $R^4$  are as defined in claim 1 except that any functional group is optionally protected;

and thereafter, optionally:

- (i) converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I;
- (ii) removing any protecting group that is present;
- (iii) forming a pharmaceutically acceptable salt.

Claim 38 (currently amended): A method for treating a breast tumour ~~sensitive to inhibition of the erbB2 receptor tyrosine kinase~~ in a warm-blooded animal in need of such treatment, which comprises administering to ~~said~~ the animal an effective amount of a quinazoline derivative of ~~the~~ formula I, or a pharmaceutically-acceptable salt thereof, as defined in claim 1.

Claim 39 (cancelled).